BIOMAT Database Logo BIOMAT Database Logo

Dawn phenomenon and purified insulins. 1984

J G Devlin

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J G Devlin
Purified insulins.
March 1977, Drug and therapeutics bulletin,
J G Devlin
Highly purified insulins.
August 1978, Diabetologia,
J G Devlin
Highly purified insulins.
February 1979, Lancet (London, England),
J G Devlin
[Dawn phenomenon].
November 1986, Harefuah,
J G Devlin
Approval of purified insulins.
November 1980, FDA drug bulletin,
J G Devlin
The new purified insulins.
June 1981, American pharmacy,
J G Devlin
Letter: Highly purified insulins.
May 1976, Lancet (London, England),
J G Devlin
[The "dawn" phenomenon].
October 1985, Medicina clinica,
J G Devlin
Dawn phenomenon and intensified therapy.
January 1983, Diabetes care,
J G Devlin
Prevention of dawn phenomenon.
January 1987, Diabetes care,
Copied contents to your clipboard!